Gastroenteropancreatic Neuroendocrine Tumors Clinical Trial
Official title:
Exploratory, Non-Interventional Study For Evaluating The Diagnostic, Prognostic And Response-Predictive Value Of A Multi Biomarker Approach In Metastatic GEP NETs
This exploratory study aims to evaluate the diagnostic, prognostic and response predictive value of a multi biomarker strategy in patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP NETs) originating from the midgut or pancreas. Using a recently developed methodology enabling the evaluation of 92 concomitant cancer biomarkers will provide an interesting approach to solve this question (Lundberg et al 2011).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02231762 -
Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET
|
Phase 2 | |
| Completed |
NCT02730104 -
Community-based Neuroendocrine Tumor (NET) Research Study
|
||
| Completed |
NCT02608203 -
[68 Ga]-DOTANOC PET/CT in GEP-NETs
|
Phase 2/Phase 3 | |
| Completed |
NCT01842165 -
177Lutetium-octreotate Treatment Prediction Using Multimodality Imaging in Refractory NETs
|
Phase 3 | |
| Terminated |
NCT02078843 -
Diagnostic Accuracy of Gallium-68-DOTATATE PET/CT Compared to Indium-111-pentetreotide Scintigraphy (SPECT/CT) for Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT02162446 -
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
|
Phase 1/Phase 2 | |
| Completed |
NCT03043664 -
Study of Pembrolizumab With Lanreotide Depot for Gastroenteropancreatic Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT04524442 -
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
|
Phase 4 | |
| Active, not recruiting |
NCT04711135 -
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
|
Phase 2 |